breast-cancer-2017-keynote

3 / 6

Volume 2, Issue 3 (Suppl) Breast Can Curr Res, an open access journal
ISSN: 2572-4118 Breast Cancer 2017
June 15-17, 2017
Page 31
Notes:
conferenceseries.com
June 15-17, 2017 London, UK
5th World Congress on
Breast Cancer
Yun Gong, Breast Can Curr Res 2017, 2:3(Suppl)
DOI: 10.4172/2572-4118-C1-004
Biomarkers that have prognostic and therapeutic importance for inflammatory breast cancer
Inflammatory breast cancer (IBC) is rare but the most lethal type of breast cancer. IBC is often associated with early metastasis
and resistance to conventional therapies. Understanding biological insights that underlie the aggressive behavior of IBC
and identifying novel therapeutic strategies are highly desirable for improvement of clinical outcome in patients with IBC.
This presentation will cover the clinic-pathologic significance of some important biomarkers expression in a cohort of IBC
that have long-term clinical follow-up and treatment information. Our results indicated that EZH2 and PD-L1 (clone 28-8)
expression status may be used to identify a subset of patients who have a relatively worse prognosis. Targeting EZH2 also may
provide a novel strategy for improving the clinical outcome of patients with IBC. In addition, androgen receptor expression
was significantly associated with lymphovascular invasion. Additional information and discussion will be presented.
Biography
Yun Gong has received her MD degree in 1984 and then finished her Postgraduate Pathology training in 1989 at Zhejiang Medical University in China. She then
worked as a Post-doctor and Research Associate in the Shanghai Institute of Cell Biology, Chinese Academy of Sciences, Catholic University of Nijmegen, the
Netherlands and the Scripps Research Institute, La Jolla, California. From 1998 to 2002, she has received her residency training in Anatomic and Clinical Pathology
at Northwestern University Medical School in Chicago, followed by one-year cytopathology fellowship training at MD Anderson Cancer Center. From 2003, she
became a Faculty Member at the Dept. of Pathology, MD Anderson Cancer Center, and currently is a Full Professor. She has numerous publications in the fields of
breast cancer research and cytopathology (120 peer-review articles, 18 invited articles, 6 book chapters and 1 book, 118 abstracts). She is an important collaborator
of two IBC research projects that were funded by Susan G Komen Promise Grant. She is a Guest Editor of Breast Diseases: Year Book of Oncology since 2011,
a Member of the study section of MD Anderson Institutional Research Grant Program, and was a reviewer for NCI/NIH on Business Innovation Research Contract
Proposals in 2009 and 2013.
Yun Gong
University of Texas-MD Anderson Cancer Center, USA